Physician profile
Mohammed Memon
NPI 1164577102
$1,065.27
in general payments reported to CMS, 2019-2025
23 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2021: $350 · 2022: $15.33 · 2023: $76.16 · 2024: $49.52 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $328 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $328.41 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $169.86 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $137.81 | 2019-2025 | |
| Janssen Biotech, INC. | $125.65 | 2019-2021 | |
| Genentech USA, INC. | $118.36 | 2019-2023 | Venclexta |
| Incyte Corporation | $109.54 | 2019-2021 | |
| Pfizer INC. | $58.80 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $58.48 | 2019-2025 | Opdivo |
| Exelixis INC. | $40.94 | 2019-2021 | |
| Celgene Corporation | $36.73 | 2019-2022 | |
| Glaxosmithkline, LLC. | $28.55 | 2025 | Blenrep, Ojjaara |
| Eisai INC. | $20.12 | 2025 | |
| Genzyme Corporation | $19.84 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.51 | 2021 | |
| Currax Pharmaceuticals LLC | $17.87 | 2021 | |
| Gilead Sciences, INC. | $17.33 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $17.32 | 2019 | |
| Rigel Pharmaceuticals, INC. | $15.28 | 2024 | Rezlidhia, Tavalisse |
| Taiho Oncology, INC. | $14.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.80 | 2019 | |
| Merck Sharp & Dohme LLC | $13.38 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.28 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.